Vancouver, British Columbia–(Newsfile Corp. – January 30, 2024) – Defense Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“defense” or “company), one of Canada's leading biotechnology companies active in the field of immuno-oncology, has announced its first biotechnology company closure.cent The previously announced non-brokered private placement tranche (“Recruitment“) Company unit (“)unit“) Total gross revenue $850,500.00 (“closureEach Unit consists of one common share in the capital of the Company (each a “share“) and one common stock purchase warrant (each, “warrant“).
Each stock acquisition right is exercisable to acquire one share at an exercise price of $2.00 per share by January 30th.th2026 (“Warrant expiration date“).
In connection with the Closing, the Company paid a cash finder's fee of $68,040.00 and issued 45,360 finder's warrants (“”).finder's warrantEach Finder's warrant is exercisable for one share at an exercise price of $2.00 per share on or before the expiration date of the warrant.
The Company will use the net proceeds from this offering to advance its preclinical and clinical programs, including the Phase I clinical trial of Defense's AccuTOX®, administered intratumorally to patients with stage IIIB to IV melanoma, as previously announced. The proceeds will be used for promotion and general working capital.
All securities issued in connection with the offering will be subject to a statutory holding period of four months plus one day from the date of issuance, in accordance with applicable securities laws.
The securities referenced in this news release have not been and will not be registered under the United States (US). securities law in 1933As amended, may not be offered or sold in the United States or to or for the account or benefit of U.S. persons absent registration or an applicable exemption from registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. .
Regarding defense:
Defense Therapeutics is a publicly traded biotechnology company working to develop next-generation vaccines and ADC products using a proprietary platform. At the core of the Defense Therapeutics platform is ACCUM® This technology allows for precise delivery of intact vaccine antigens or ADCs to target cells. The result is increased effectiveness and potency against devastating diseases such as cancer and infectious diseases.
For more information:
Sebastian Plouffe, President, CEO, Director
Phone: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Notes regarding “forward-looking” information
This release contains certain statements that may be considered “forward-looking statements.” All statements, other than statements of historical fact, in this release about events or developments that the Company expects to occur are forward-looking statements. Forward-looking statements are statements that are not historical facts and generally include, but are not limited to, “expect,” “plan,” “anticipate,” “believe,” “intend,” or “estimate.” , identified by the word “to plan.” , “potential” and similar expressions, or when an event or condition “will”, “will”, “could”, “could”, or “should” occur. “There is.” Such forward-looking statements include, without limitation, the use of the proceeds from our offering. Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. The content may differ significantly. Factors that could cause actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, the continued availability of capital and financing and general economic, market, or business situations. Investors are cautioned that such statements are not guarantees of future performance and actual results or developments may differ materially from those anticipated in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates, opinions or other factors change. not.
Neither the CSE nor its market regulator accepts responsibility for the adequacy or accuracy of this release as that term is defined in the policies of the CSE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/196242.
